<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146457</url>
  </required_header>
  <id_info>
    <org_study_id>2009P000197</org_study_id>
    <nct_id>NCT01146457</nct_id>
  </id_info>
  <brief_title>The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia</brief_title>
  <official_title>The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the ideal dosage of intrathecal morphine for intra
      and post partum analgesia, while minimizing the side effect profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regional anesthesia techniques such as combined spinal epidural (CSE) analgesia are very
      effective for the management of intrapartum pain. The advantages of these techniques are that
      they are safe when properly conducted and that they provide excellent analgesia while
      allowing the patient to remain awake and participate in the labor and delivery. The risks of
      maternal aspiration and fetal drug depression associated with general anesthesia are
      minimized. Finally, the effective analgesia associated with regional techniques blunt the
      hemodynamic effects caused by painful contractions and reduce maternal catecholamines,
      resulting in increased placental perfusion.1

      Opioids in combination with local anesthetics in the spinal space provide effective pain
      relief during labor with minimal side effects. The advantages of spinal opioid administration
      include lack of motor blockade and faster onset of analgesia.2 In addition, since the opiate
      receptors are in the spinal space, a smaller amount of opioid can be used to provide
      excellent pain relief while minimizing the side effects. At Beth Israel Deaconess Medical
      Center (BIDMC), the obstetric anesthesiology group uses a standard spinal dosing for CSE
      during labor which includes: 1 ml of 0.25% bupivicaine with 12.5 mcg of fentanyl.

      Yeh and colleagues have found that morphine 150 mcg added to the fentanyl-bupivicaine spinal
      injection can prolong the duration of spinal analgesia but was associated with increased side
      effects. 3 The side effect profile of spinal narcotics include: nausea, vomiting, pruritus,
      and urinary retention. Although these side effects for the most part can be easily treated,
      they can be bothersome to the post partum patient. In a previous study performed from our
      institution, the addition of 100 mcg of morphine to spinal bupivicaine and fentanyl reduced
      the rate of breakthrough pain during labor analgesia and prolonged the time to first request
      for supplementation. Overall, it was found that the incidence of side effects was low but the
      group that received the spinal morphine did have more nausea and vomiting compared with the
      placebo group. 4

      In this current investigation, we would like to assess whether an even smaller dose of spinal
      morphine would provide an effective, pain free recovery from vaginal delivery while
      decreasing the incidence of side effects, specifically nausea and vomiting. We would like to
      perform a formal dose response study to identify the ideal dose of intrathecal morphine that
      would not compromise the pain relief during labor while minimizing the side effects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Breakthrough Pain</measure>
    <time_frame>Participants were followed for the duration of delivery, an average of 7 hours</time_frame>
    <description>Rate of breakthrough pain is the number of episodes of breakthrough pain divided by the number of hours of labor. Time measured from placement of the neuraxial anesthetic, until delivery of the neonate. Because duration of labor is different for all patients, the rate of breakthrough pain per hour is used as the primary outcome.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Labor Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine 25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine 50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine 75</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Active dosage</description>
    <arm_group_label>Morphine 25</arm_group_label>
    <arm_group_label>Morphine 50</arm_group_label>
    <arm_group_label>Morphine 75</arm_group_label>
    <arm_group_label>Morphine 100</arm_group_label>
    <other_name>Dose of morphine added to solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline Control</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline added to solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton pregnancy,

          -  at least 36 weeks gestational age,

          -  active labor (â‰¤ 5 cm dilation) requesting neuraxial analgesia,

          -  ASA I or II,

          -  not currently taking pain medications.

        Exclusion Criteria:

          -  multiple gestation,

          -  preterm labor,

          -  systemic opioids in the past 4 hours,

          -  chronic pain syndromes,

          -  chronic opioid use,

          -  contraindications to regional anesthesia,

          -  allergies to opioids,

          -  significant co existing medical problems,

          -  severe pregnancy induced hypertension,

          -  sedatives,

          -  magnesium therapy,

          -  diabetes type 1.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip E Hess, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <results_first_submitted>August 5, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Phillip Hess</investigator_full_name>
    <investigator_title>Chief of Obstetric Anesthesia</investigator_title>
  </responsible_party>
  <keyword>Obstetric anesthesia</keyword>
  <keyword>labor analgesia</keyword>
  <keyword>morphine</keyword>
  <keyword>epidural analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Saline: Saline Control</description>
        </group>
        <group group_id="P2">
          <title>Morphine 25</title>
          <description>Morphine 25 micrograms: Active dosage</description>
        </group>
        <group group_id="P3">
          <title>Morphine 50</title>
          <description>Morphine 50 micrograms: Active dosage</description>
        </group>
        <group group_id="P4">
          <title>Morphine 75</title>
          <description>Morphine 75 micrograms: Active dosage</description>
        </group>
        <group group_id="P5">
          <title>Morphine 100</title>
          <description>Morphine 100 micrograms: Active dosage</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Saline control</description>
        </group>
        <group group_id="B2">
          <title>Morphine 25</title>
          <description>Morphine 25 micrograms</description>
        </group>
        <group group_id="B3">
          <title>Morphine 50</title>
          <description>Morphine 50 micrograms</description>
        </group>
        <group group_id="B4">
          <title>Hine 75</title>
          <description>Morphine 75 micrograms</description>
        </group>
        <group group_id="B5">
          <title>Morphine 100</title>
          <description>Morphine 100 micrograms</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" spread="5.3"/>
                    <measurement group_id="B2" value="31.5" spread="5.3"/>
                    <measurement group_id="B3" value="31.3" spread="6.6"/>
                    <measurement group_id="B4" value="32.5" spread="5.5"/>
                    <measurement group_id="B5" value="32.4" spread="5.7"/>
                    <measurement group_id="B6" value="32.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Breakthrough Pain</title>
        <description>Rate of breakthrough pain is the number of episodes of breakthrough pain divided by the number of hours of labor. Time measured from placement of the neuraxial anesthetic, until delivery of the neonate. Because duration of labor is different for all patients, the rate of breakthrough pain per hour is used as the primary outcome.</description>
        <time_frame>Participants were followed for the duration of delivery, an average of 7 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Saline Control</description>
          </group>
          <group group_id="O2">
            <title>Morphine 25</title>
            <description>Morphine 25 micrograms</description>
          </group>
          <group group_id="O3">
            <title>Morphine 50</title>
            <description>Morphine 50 micrograms</description>
          </group>
          <group group_id="O4">
            <title>Morphine 75</title>
            <description>Morphine 75 micrograms</description>
          </group>
          <group group_id="O5">
            <title>Morphine 100</title>
            <description>Morphine 100 micrograms</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Breakthrough Pain</title>
          <description>Rate of breakthrough pain is the number of episodes of breakthrough pain divided by the number of hours of labor. Time measured from placement of the neuraxial anesthetic, until delivery of the neonate. Because duration of labor is different for all patients, the rate of breakthrough pain per hour is used as the primary outcome.</description>
          <units>episodes of breakthrough pain per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.29"/>
                    <measurement group_id="O2" value="0.28" spread="0.35"/>
                    <measurement group_id="O3" value="0.25" spread="0.25"/>
                    <measurement group_id="O4" value="0.23" spread="0.26"/>
                    <measurement group_id="O5" value="0.17" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Saline: Saline Control</description>
        </group>
        <group group_id="E2">
          <title>Morphine 25</title>
          <description>Morphine: Active dosage</description>
        </group>
        <group group_id="E3">
          <title>Morphine 50</title>
          <description>Morphine: Active dosage</description>
        </group>
        <group group_id="E4">
          <title>Morphine 75</title>
          <description>Morphine: Active dosage</description>
        </group>
        <group group_id="E5">
          <title>Morphine 100</title>
          <description>Morphine: Active dosage</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Philip Hess</name_or_title>
      <organization>BIDMC</organization>
      <phone>617-667-3353</phone>
      <email>phess@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

